(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(0.38%) $78.41
(0.33%) $2.15
(0.42%) $2 318.30
(1.82%) $27.18
(-0.26%) $962.80
(0.03%) $0.929
(-0.06%) $10.87
(0.00%) $0.797
(0.00%) $91.45
25.00% € 20.60
Live Chart Being Loaded With Signals
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally...
Stats | |
---|---|
Dzisiejszy wolumen | 290 930 |
Średni wolumen | 0 |
Kapitalizacja rynkowa | 0.00 |
EPS | €0.230 ( 2022-06-29 ) |
Last Dividend | €0.163 ( 2022-08-18 ) |
Next Dividend | €0 ( N/A ) |
P/E | 17.31 |
ATR14 | €0 (0.00%) |
GSK plc Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
GSK plc Finanse
Annual | 2021 |
Przychody: | €34.11B |
Zysk brutto: | €22.51B (65.99 %) |
EPS: | €1.102 |
FY | 2021 |
Przychody: | €34.11B |
Zysk brutto: | €22.51B (65.99 %) |
EPS: | €1.102 |
FY | 2020 |
Przychody: | €34.10B |
Zysk brutto: | €22.40B (65.68 %) |
EPS: | €1.426 |
FY | 2019 |
Przychody: | €33.75B |
Zysk brutto: | €21.89B (64.85 %) |
EPS: | €1.158 |
Financial Reports:
No articles found.
GSK plc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0.163 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.140 | 2004-02-18 |
Last Dividend | €0.163 | 2022-08-18 |
Next Dividend | €0 | N/A |
Payout Date | 2022-10-06 | |
Next Payout Date | N/A | |
# dividends | 75 | -- |
Total Paid Out | €12.75 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.13 | -- |
Div. Sustainability Score | 8.49 | |
Div.Growth Potential Score | 4.03 | |
Div. Directional Score | 6.26 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
HYI.F | No Dividend Player | 2023-06-19 | Annually | 0 | 0.00% | |
SWF.DE | Ex Dividend Junior | 2023-09-01 | Quarterly | 0 | 0.00% | |
CE2.DE | Ex Dividend Junior | 2023-07-12 | Annually | 0 | 0.00% | |
LEI.DE | Ex Dividend Junior | 2023-06-08 | Annually | 0 | 0.00% | |
VH2.F | Ex Dividend Junior | 2023-06-02 | Annually | 0 | 0.00% | |
DWD.DE | Ex Dividend Junior | 2023-07-28 | Quarterly | 0 | 0.00% | |
NOEJ.DE | Ex Dividend Junior | 2023-05-12 | Annually | 0 | 0.00% | |
6MK.DE | Ex Dividend Knight | 2023-09-14 | Quarterly | 0 | 0.00% | |
FRE.DE | Ex Dividend Junior | 2023-05-18 | Annually | 0 | 0.00% | |
PTTG.F | Ex Dividend Knight | 2023-08-15 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.149 | 1.500 | 7.01 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0644 | 1.200 | 7.85 | 9.42 | [0 - 0.3] |
returnOnEquityTTM | 0.344 | 1.500 | 7.29 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.785 | -1.000 | 2.15 | -2.15 | [0 - 1] |
currentRatioTTM | 0.789 | 0.800 | -1.055 | -0.844 | [1 - 3] |
quickRatioTTM | 0.183 | 0.800 | -3.63 | -2.90 | [0.8 - 2.5] |
cashRatioTTM | 0.181 | 1.500 | -0.108 | -0.162 | [0.2 - 2] |
debtRatioTTM | 0.306 | -1.500 | 4.91 | -7.36 | [0 - 0.6] |
interestCoverageTTM | 7.03 | 1.000 | 8.51 | 8.51 | [3 - 30] |
operatingCashFlowPerShareTTM | 1.998 | 2.00 | 9.33 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 1.261 | 2.00 | 9.37 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 1.606 | -1.500 | 3.58 | -5.37 | [0 - 2.5] |
grossProfitMarginTTM | 0.660 | 1.000 | 2.34 | 2.34 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.162 | 1.000 | 8.77 | 8.77 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.329 | 1.000 | 9.28 | 9.28 | [0.2 - 2] |
assetTurnoverTTM | 0.431 | 0.800 | -0.458 | -0.367 | [0.5 - 2] |
Total Score | 8.49 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 13.80 | 1.000 | 8.71 | 0 | [1 - 100] |
returnOnEquityTTM | 0.344 | 2.50 | 8.26 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 1.261 | 2.00 | 9.58 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 1.998 | 2.00 | 9.33 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.785 | 1.500 | 2.15 | -2.15 | [0 - 1] |
pegRatioTTM | -0.326 | 1.500 | -5.51 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.233 | 1.000 | 6.67 | 0 | [0.1 - 0.5] |
Total Score | 4.03 |
GSK plc
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej